前瞻性国际多族裔队列中射血分数保留与降低心衰的死亡率比较
该前瞻性多中心纵向研究在新西兰和新加坡纳入2039例心衰患者,比较HFpEF、HFmrEF和HFrEF的特征与结局。随访2年,HFpEF患者全因死亡风险低于HFrEF(HR 0.62,95%CI 0.46-0.85),NT-proBNP在三表型中独立且相似地预测死亡。
要点
- HFpEF占心衰人群28%,HFmrEF占13%,HFrEF占59%。
- 校正年龄、性别和临床危险因素后,HFpEF死亡风险低于HFrEF(HR 0.62,95%CI 0.46-0.85)。
- NT-proBNP在三表型中独立且相似地预测死亡。
核心结论
- HFpEF在心衰人群中的患病率低于HFrEF,其死亡风险也低于HFrEF,而HFpEF与HFmrEF的死亡率相当。
- 血浆NT-proBNP水平独立且相似地预测HFpEF、HFmrEF和HFrEF三种表型的死亡。
研究设计与样本
- 前瞻性多中心纵向研究,在新西兰和新加坡开展,纳入2039例心衰患者,基线评估并随访2年。
- 主要结局为全因死亡,次要结局为死亡和心衰住院,采用Cox比例风险模型比较三种心衰表型的结局。
主要发现
- 2039例患者中,HFpEF占28%,HFmrEF占13%,HFrEF占59%。
- 与HFrEF相比,HFpEF患者年龄更大(62 vs. 72岁),女性更常见(17% vs. 48%),高血压病史更常见(61% vs. 78%),冠心病史较少(55% vs. 41%)。
- 2年随访期间343例(17%)患者死亡。
- 校正年龄、性别和临床危险因素后,HFpEF患者死亡风险低于HFrEF(HR 0.62,95%CI 0.46-0.85)。
- NT-proBNP与三种心衰表型的死亡关联独立于所列协变量和射血分数,且结果在新加坡和新西兰间一致。
关键数值与推荐
- HFpEF定义为射血分数保留,HFmrEF定义为射血分数40-49%,HFrEF定义为射血分数降低。
- 校正年龄、性别和临床危险因素后,HFpEF对比HFrEF的死亡风险HR为0.62(95%CI 0.46-0.85)。
临床怎么用
- 在临床中应认识到HFpEF患者死亡风险虽低于HFrEF,但仍需积极管理。
- NT-proBNP可用于三种心衰表型的死亡风险预测。
局限性
- 研究仅在新西兰和新加坡两个国家进行,结果外推需谨慎。
- 随访时间为2年,长期结局未明。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
AIMS: Whether prevalence and mortality of patients with heart failure with preserved or mid-range (40-49%) ejection fraction (HFpEF and HFmREF) are similar to those of heart failure with reduced ejection fraction (HFrEF), as reported in some epidemiologic studies, remains highly controversial. We determined and compared characteristics and outcomes for patients with HFpEF, HFmREF, and HFrEF in a prospective, international, multi-ethnic population. METHODS AND RESULTS: Prospective multi-centre longitudinal study in New Zealand (NZ) and Singapore. Patients with HF were assessed at baseline and followed over 2 years. The primary outcome was death from any cause. Secondary outcome was death and HF hospitalization. Cox proportional hazards models were used to compare outcomes for patients with HFpEF, HFmrEF, and HFrEF. Of 2039 patients enrolled, 28% had HFpEF, 13% HFmrEF, and 59% HFrEF. Compared with HFrEF, patients with HFpEF were older (62 vs. 72 years), more commonly female (17% vs. 48%), and more likely to have a history of hypertension (61% vs. 78%) but less likely to have coronary artery disease (55% vs. 41%). During 2 years of follow-up, 343 (17%) patients died. Adjusting for age, sex, and clinical risk factors, patients with HFpEF had a lower risk of death compared with those with HFrEF (hazard ratio 0.62, 95% confidence interval 0.46-0.85). Plasma (NT-proBNP) was similarly related to mortality in both HFpEF, HFmrEF, and HFrEF independent of the co-variates listed and of ejection fraction. Results were similar for the composite endpoint of death or HF and were consistent between Singapore and NZ. CONCLUSION: These prospective multinational data showed that the prevalence of HFpEF within the HF population was lower than HFrEF. Death rate was comparable in HFpEF and HFmrEF and lower than in HFrEF. Plasma levels of NT-proBNP were independently and similarly predictive of death in the three HF phenotypes. TRIAL REGISTRATION: Australian New Zealand Clinical Trial Registry (ACTRN12610000374066).
引用
- Lam CSP, Gamble GD, Ling LH, et al. Mortality associated with heart failure with preserved vs. reduced ejection fraction in a prospective international multi-ethnic cohort study. Eur Heart J. 2018. PMID: 29390051. doi:10.1093/eurheartj/ehy005
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。